Market Newsdesk

MIGDAL HAEMEK, Israel, Nov. 18, 2020 /PRNewswire/ — Camtek Ltd. (NASDAQ: CAMT) (TASE: CAMT), a leading manufacturer of metrology and inspection equipment, announced today the commencement of a proposed underwritten public offering of three million ordinary shares. Camtek intends to grant the underwriters a 30-day option to purchase up to an additional 15% of its ordinary shares offered in the public offering.  All of the shares in the proposed offering are to be sold by Camtek.

Camtek intends to use the net proceeds from the offering for general corporate purposes, including, but not limited to, potential acquisitions, working capital, capital expenditures, investments, research and development and product development. Camtek has not determined the amount of net proceeds to be used specifically for the foregoing purposes and has no agreements or understandings with respect to any acquisition or investment at this time.

Barclays and Stifel are acting as the representatives of the underwriters and as joint book-running managers for the proposed offering.

The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

The securities described above are being offered by Camtek pursuant to an effective shelf registration statement on Form F-3, including a base prospectus, that was previously filed by Camtek with the Securities and Exchange Commission (the “SEC“) and that was declared effective on April 21, 2020. This offering will be made only by means of a prospectus supplement and the accompanying prospectus which forms a part of the effective shelf registration statement.

Before you invest, you should read the prospectus included in the registration statement, the preliminary prospectus supplement and the other documents Camtek has filed or will file with the SEC for more complete information about Camtek and the proposed offering. You may obtain these documents for free by visiting EDGAR on the SEC’s website located at http://www.sec.gov. Alternatively, copies of the preliminary prospectus supplement, when available, and the accompanying base prospectus relating to the proposed offering may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847 or by email at [email protected], or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Camtek

Camtek is a leading manufacturer of metrology and inspection equipment serving the Advanced Interconnect Packaging, Memory, CMOS Image Sensors, MEMS, RF and other segments of the semiconductor industry. Camtek provides dedicated inspection solutions and crucial yield-enhancement data, enabling manufacturers to improve yield and drive down their production costs. With eight offices around the world, Camtek has best-in-class sales and customer support organization, providing tailor-made solutions in line with customers’ requirements.

Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations and assumptions of Camtek Ltd. (“we,” “us” and “our”). Forward-looking statements can be identified by the use of words including “believe,” “anticipate,” “should,” “intend,” “plan,” “will,” “may,” “expect,” “estimate,” “project,” “positioned,” “strategy,” and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Camtek to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including as a result of the effect of the COVID-19 crisis on the global markets and on the markets in which we operate, including the risk of the continuation of disruptions to our and our customers’, providers’, business partners and contractors’ businesses as a result of the COVID-19 pandemic; our dependency upon the semiconductor industry and the risk that unfavorable economic conditions or low capital expenditures may negatively impact our operating results; the highly competitive nature of the markets we serve, some of which have dominant market participants with greater resources than us; the rapid evolvement of technology in the markets in which we operate, and our ability to adequately predict these changes or keep pace with emerging industry standards; the risks relating to the concentration of a significant portion of our business in certain countries in the Asia Pacific Region, particularly China, Taiwan and Korea; changing industry and market trends; reduced demand for our products; the timely development of our new products and their adoption by the market; increased competition in the industry; price reductions; and those other factors discussed in our Annual Report on Form 20-F and other documents filed by the Company with the SEC as well as other documents that may be subsequently filed by Camtek from time to time with the SEC.

While we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. In addition, any forward-looking statements represent Camtek’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Camtek does not assume any obligation to update any forward-looking statements unless required by law. 

View original content:http://www.prnewswire.com/news-releases/camtek-announces-commencement-of-public-offering-of-ordinary-shares-301175665.html

SOURCE Camtek Ltd

BEIJING, Nov. 18, 2020 /PRNewswire/ — Puxin Limited (NYSE: NEW) (“Puxin” or the “Company”), a successful consolidator of the after-school education industry in China, today announced that Mr. Yun Xiao has resigned as the Company’s Chief Operating Officer due to personal reasons.

Mr. Yunlong Sha, Chairman and Chief Executive Officer, commented, “We greatly value Yun’s contributions to Puxin during his journey with the Company and wish him success in all his future endeavors. Puxin will further implement our Online-Merge-Offline strategy nationwide to expand student outreach. We will dedicate ourselves to continued profitable growth.”

Safe Harbor Statement

This press release contains forward-looking statements made under the “safe harbor” provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “may,” “would,” “expect,” “anticipate,” “future,” “intend,” “aim,” “plan,” “believe,” “estimate,” “predict,” “project,” “continue,” “confident” and similar statements. The Company may also make written or oral forward-looking statements in its reports filed with or furnished to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements that involve factors, risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors and risks include, but not limited to the following: its goals and strategies, its ability to achieve and maintain profitability, its ability to attract and retain students to enroll in its courses, its ability to effectively manage its business expansion and successfully integrate businesses it acquired, its ability to identify or pursue targets for acquisitions, its ability to compete effectively against its competitors, its ability to improve the content of its existing courses or to develop new courses, and relevant government policies and regulations relating to the Company’s corporate structure, business and industry. Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is current as of the date of the press release, and the Company does not undertake any obligation to update such information, except as required under applicable law.

About Puxin Limited

Puxin Limited (NYSE: NEW, “Puxin” or the “Company”) is a successful consolidator of the after-school education industry in China. Puxin has a strong acquisition and integration expertise to effectively improve education quality and operational performance of acquired schools. Puxin offers a full spectrum of K-12 and study-abroad tutoring programs designed to help students achieve academic excellence, as well as prepare for admission tests and applications for top schools, universities and graduate programs in China and other countries. The Company has developed a business model effectively combining strategic acquisitions and organic growth achieved through successful post-acquisition integration, which has differentiated the Company from other after-school education service providers in China. For more information, please visit http://www.pxjy.com/.

Contacts

Puxin Limited
Phone: +86-10-6269-8930
E-mail: [email protected]

Institutional Capital Advisory (ICA)

Mr. Kevin Yang
Phone: +86-021-8028-6033
E-mail: [email protected]

View original content:http://www.prnewswire.com/news-releases/puxin-limited-announces-departure-of-chief-operating-officer-301175505.html

SOURCE Puxin Limited

HANGZHOU, China and SHAOXING, China, Nov. 18, 2020 /PRNewswire/ — Ascletis Pharma Inc. (HKEX code: 1672) announces today that the board of directors of the Company (the “Board”) resolved to change the use of the remaining Net Proceeds from the Global Offering. (see announcement: https://www.ascletis.com/Index/index/relation/cate_id/150.html)

The main reasons for the changes in the proposed applications of the Net Proceeds and reallocation of the unutilized amount of the Net Proceeds are as follows:

(a) The proportion of the Net Proceeds to be used in continued research and development of the Company’s pipeline products has been raised from approximately 65% to 75% in total, primarily for the purpose of expansion of R&D portfolio into two new disease areas: hepatitis B clinical cure and NASH.

(b) The Prospectus stipulates that approximately 10.0% of the Net Proceeds is originally intended to be used for the Group’s research and development of ASC21, which is an IND-approved NS5B polymerase nocleot(s)ide inhibitor licensed from Medivir AB under the exclusive licensing agreement executed in June 2017. The Company and Medivir AB agreed to cease the cooperation on November 17, 2020. The Company also ceased utilization the Company’s resources for the research and development of ASC21, and ASC21 is no longer a pipeline product of the Company. The Company currently has another IND-approved HCV dual-targeted fixed-dose combination (FDC) candidate in its pipeline, ASC18, which is in-house developed, one-pill once-a-day FDC as the complete treatment of hepatitis C. ASC18 FDC consists of two DAAs: Ravidasvir, an NS5A inhibitor and Sofosbuvir, an NS5B polymerase nocleot(s)ide inhibitor. Since ASC21 is also an NS5B polymerase nocleot(s)ide inhibitor, which intended to be combined with Ravidavir as FDC, ceasing cooperation with Medivir AB does not have material impact on the Company’s HCV pipeline.

(c) The Prospectus stipulates that approximately 25.0% of the Net Proceeds is originally intended to be used for the Group’s commercialization of Ganovo® and Ravidasvir. However, since all oral regimens have become standard for HCV treatment in 2020, Ganovo® (Danoprevir) in combination with injectable peginterferon is no longer an option for many HCV patients, the Company intends to reduce from approximately 25% to 18% of this portion of the Net Proceeds and re-allocate mainly to continued research and development of the Core Product pipeline in viral hepatitis, NASH, HIV/AIDS.

“Since Hong Kong IPO in 2018, Ascletis has developed from a single disease – HCV platform into multi-disease platform including viral hepatitis, NASH and HIV/AIDS,”  said Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis, “The change in use of Proceeds from the Global Offering makes more resources available to support our global leading pipelines for hepatitis B clinical cure and NASH.”

About Ascletis

Ascletis is an innovative R&D driven biotech with two commercial products and listed on Hong Kong Stock Exchange (Ascletis, 1672.HK). Ascletis is committed to developing and commercializing antiviral, steatohepatitis, and tumor-related innovative drugs for unmet medical needs in China and Globally. Led by a management team with deep expertise and a proven track record, Ascletis has developed into a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Ascletis’ pipeline is focused primarily on three therapeutic areas: 1. HCV: one commercial stage product, one near commercial stage drug and two R&D stage drug candidates. Ganovo® (Danoprevir) is the first direct-acting anti-viral agent for hepatitis C, developed by a domestic firm in China. 2. HBV: one commercial stage product and three R&D stage drug candidates. Pegasys® (Peginterferon alfa-2a) is a leading marketed pegylated interferon for hepatitis B&C partnered with Roche. 3. NASH (Non-Alcoholic SteatoHepatitis): three R&D stage drug candidates against three different targets for combination treatments. For more information, please visit www.ascletis.com.

View original content:http://www.prnewswire.com/news-releases/change-in-use-of-proceeds-from-the-global-offering-for-expansion-of-rd-portfolio-into-hepatitis-b-clinical-cure-and-nash-301175645.html

SOURCE Ascletis Pharma Inc.

MILAN, Nov. 18, 2020 /PRNewswire/ — Prysmian Group, world leader in the energy and telecom cables systems industry, confirmed with improved score, to 86 points from 84 points in 2019, in the ELQ Electrical Components & Equipments on the Dow Jones Sustainability World index, according to the result of the 2020 annual review conducted by S&P Global CSA. Prysmian is the only pure cable maker included in the most recognized sustainability index at global level, covering over 3,400 companies.

“We are very proud of this important achievement – commented Valerio Battista CEO of Prysmian Group – as it recognizes our commitment in constantly improve the sustainability of our operations, supply chain and organization. Sustainability is also integrated as a fundamental part of our business growth strategy. We are strongly committed to support the transition to renewable energy resources as well as to a digitalized and decarbonized world, by making available the most advanced cables and optical fiber technology for power grids and telecom networks”.

Prysmian achieved the best results in Innovation Management – where last year’s score was maintained -, in Environmental Reporting, Social Reporting and Talent Attraction & Retention where the score was improved.

At Prysmian Group, we strongly believe that Sustainability and Innovation are linked together. We have embarked on a comprehensive innovation effort including product carbon footprint, circular economy and low carbon product innovations for Energy transition and Digitalization.

Innovations like P-Laser, the first totally recyclable cable ensuring higher and more reliable performances, can contribute to the development of more performing and sustainable power grids. P Laser HVDC cable technology was chosen for the development of German Corridors, a milestone of the energy transition projects. Prysmian is also committed to sustainable innovation in the field of the optical fibre and cable for telecom networks, as demonstrated with the recent launch of a pilot project with the Dutch telecom operator KPN involving a fibre-optic network containing 90% recycled plastic.

Next November 24^th, Prysmian is launching a

Sustainability Day
 and three interactive online workshops in a new all-digital format for its annual Stakeholder Engagement event, an important appointment to shape priorities for the Group’s sustainability strategy. Sustainability goals are achieved by working with our partners. The stakeholder engagement is a key part of Prysmian Group’s sustainability strategy.

In 2020 Prysmian Group joined the international business community in the 50 Sustainability and Climate Leaders, a forum where companies share their ideas and experience in responding to climate change, hosted on Bloomberg website and 50 climate leaders hub.

Prysmian Group

Prysmian Group is world leader in the energy and telecom cable systems industry. With almost 140 years of experience, sales of over €11 billion, about 29,000 employees in over 50 countries and 106 plants, the Group is strongly positioned in high-tech markets and offers the widest possible range of products, services, technologies and know-how. It operates in the businesses of underground and submarine cables and systems for power transmission and distribution, of special cables for applications in many different industries and of medium and low voltage cables for the construction and infrastructure sectors. For the telecommunications industry, the Group manufactures cables and accessories for voice, video and data transmission, offering a comprehensive range of optical fibres, optical and copper cables and connectivity systems. Prysmian is a public company, listed on the Italian Stock Exchange in the FTSE MIB index.

Media Relations       
Lorenzo Caruso   
Corporate and Business Communications Director   
[email protected] 
+39-340-199-8783 

Investor Relations
Cristina Bifulco  
Investor Relations Director
[email protected]          

Andrea Andreoni

+393401998783

View original content to download multimedia:http://www.prnewswire.com/news-releases/prysmian-confirmed-with-improved-scoring-on-the-dow-jones-sustainability-world-index-301175185.html

SOURCE Prysmain S.p.A